Japanese Society of Anxiety and Related Disorders, Tokyo, Japan.
Japanese Society of Neuropsychopharmacology, Tokyo, Japan.
Neuropsychopharmacol Rep. 2023 Sep;43(3):288-309. doi: 10.1002/npr2.12365. Epub 2023 Aug 25.
The development of clinical practice guidelines for social anxiety disorder began in March 2018 when the Joint Clinical Practice Guideline Development Committee for Anxiety and Obsessive-Compulsive Disorders was formed by the Japanese Society of Anxiety and Related Disorders and Japanese Society of Neuropsychopharmacology to jointly develop guidelines for anxiety and obsessive-compulsive disorders. Based on the universal concept of evidence-based medicine, three clinical questions (CQs) about pharmacotherapy and psychotherapy were developed for clinical guidelines for social anxiety disorder, panic disorders, and obsessive-compulsive disorder in accordance with the Minds "Manual for Guidelines Development 2017 by the Japan Council for Quality Health Care: CQ1-"What is the recommended pharmacotherapy for social anxiety disorder in adults?"; CQ2-"What is the recommended psychotherapy (psychological intervention) for social anxiety disorder in adults?"; and CQ3-"What are the recommendations regarding monotherapy and combination therapy for social anxiety disorder in adults in terms of pharmacotherapy and psychotherapy (psychological interventions)?" Summarized recommendations for social anxiety disorder in adults are selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitor for CQ1, cognitive behavioral therapy for CQ2, and there are no recommendations regarding monotherapy and combination therapy for CQ3. These were answered by considering the balance between benefits and harms based on systematic reviews of each. The aim of this brief guideline for the standard-of-care (i.e., medical treatment) for social anxiety disorder in adults (18 years and older) was to help "shared decision making," in which medical professionals, including physicians, and patients share scientific evidence to decide on a course of treatment.
社交焦虑障碍临床实践指南的制定始于 2018 年 3 月，当时日本焦虑和相关障碍学会与日本神经精神药理学学会成立了联合临床实践指南制定委员会，共同制定焦虑和强迫症的指南。基于循证医学的普遍概念，根据日本医疗质量改善协会的“2017 年指南制定手册：CQ1-成人社交焦虑障碍的推荐药物治疗是什么？”、“CQ2-成人社交焦虑障碍的推荐心理治疗（心理干预）是什么？”和“CQ3-成人社交焦虑障碍的药物治疗和心理治疗（心理干预）的单一疗法和联合疗法有哪些建议？”三个临床问题（CQs）被制定出来，用于社交焦虑障碍、恐慌症和强迫症的临床指南。对于 CQ1，总结出了成人社交焦虑障碍的推荐药物治疗为选择性 5-羟色胺再摄取抑制剂和 5-羟色胺去甲肾上腺素再摄取抑制剂；对于 CQ2，总结出了成人社交焦虑障碍的推荐心理治疗为认知行为疗法；对于 CQ3，没有关于单一疗法和联合疗法的建议。这些建议是根据对每个问题的系统评价，在权衡利弊的基础上得出的。本成人社交焦虑障碍标准治疗（即医疗）简要指南的目的是帮助“共同决策”，即医疗专业人员（包括医生）和患者共同分享科学证据，以决定治疗方案。
